RxDoctor Payments Data

Jayasheel Eshcol, MD

Interventional Cardiology · Independence, MONPI 1770719346

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (38.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 23.3%. Reporting peaked in 2024 at $18,057 and has fallen 63.6% since, to $6,573 in 2025.

$48,885in general payments, 2019–2025

Across 715 payments — averaging $68.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Abbott$10K
  • Shockwave Medical, Inc$9K
  • Boston Scientific$8K
  • Inari Medical, Inc.$2K
  • Edwards Lifesciences$2K
  • plus $8K from 39 others
$185,467in research payments, 2019–2025

Across 23 payments — averaging $8063.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$119K
  • Janssen Research & Development, LLC$61K
  • Medtronic$5K

What the payments were for

  • Consulting fees$2,4455%
  • Speaking & faculty fees$11,86624%
  • Travel & lodging$15,66332%
  • Food & beverage$18,83639%
  • Education$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,885 in reported general payments places this provider in the 85th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$174,842
Medicare patients
385
Services billed
1,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin110$150,624
EliquisApixaban115$114,542
EntrestoSacubitril/Valsartan42$51,145
XareltoRivaroxaban31$35,606
OzempicSemaglutide15$33,196
Repatha SureclickEvolocumab29$25,317
Repatha SyringeEvolocumab18$14,364
FarxigaDapagliflozin Propanediol13$14,310
Prasugrel Hcl33$2,389
Metoprolol Succinate156$2,245
Diltiazem 12hr ErDiltiazem Hcl11$2,155
ClopidogrelClopidogrel Bisulfate174$1,942
Atorvastatin Calcium191$1,788
Telmisartan50$1,656
Enoxaparin Sodium15$1,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$97$150,624110 claims
PfizerEliquis$343$114,542115 claims
NovartisEntresto$507$51,14542 claims
Johnson & JohnsonXarelto$330$35,60631 claims
Novo NordiskOzempic$397$33,19615 claims
AstraZenecaFarxiga$115$14,31013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →